SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (5133)8/13/1998 11:06:00 AM
From: Joe E.  Read Replies (1) | Respond to of 6136
 
margie:

Rearding your previous posts about (among other things)the side effects of Sustiva:

What hits me is the birth defect issue. I don't see how a doctor could give the drug to any woman of childbearing age, knowing there is a possibility for pregnancy. How are other drugs that might cause birth defects handled? Are they prescribed to women of childbearing age so long as there is contraception? There was recently the big hoopla about Thalidomide, but that is probably hyped for political reasons.

Speaking of politics, what was Canada doing delaying normal access to the best treatment to their sick adults? Hoping they would die off??



To: margie who wrote (5133)8/13/1998 1:34:00 PM
From: John F Beule  Respond to of 6136
 
My whole investment in AGPH has been a "tax-free event". :-)

John

I think the spinoff is more a corporate move to attract and keep scientists working at specific divisions of AGPH (here are your stock options Dr., directly tied to your dept's performance), and not so much for the benefit of outsiders holding the stock as part of an investment portfolio.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News